Proof of concept demonstrates continuous-flow buffer exchange with stable nano-ESI.
First NexChip prototype achieves sub-2-second prep times with therapeutic proteins.
Company incorporated; $3.6M seed round closes with participation from Merck and Verily.
Pilot placements at leading pharma R&D labs validate >95% buffer-exchange efficiency.
NexChip Z1 enters precommercial rollout with 10 pharma and CRO partners.